Co-Diagnostics, Inc. (NASDAQ:CODX) is set to announce second quarter earning results on Thursday 13th August 2020, after market close.
Analysts surveyed by Thomson Reuters are predicting, CODX to report 2Q20 income of $ 0.59 per share.
For the full year, analysts anticipate top line of $ 93.45 million, while looking forward to income of $ 2.06 per share bottom line.
Previous Quarter Performance
Co-Diagnostics, Inc. communicated loss for the first quarter of $ 0.05 per share, from the revenue of $ 1.55 million. The quarterly revenues surged 434.48 percent compared with the same quarter last year. Wall street analysts are predicting, CODX to report 1Q20 loss of $ 0.05 per share from revenue of $ 0.62 million. The bottom line results street analysts by $ 0 or , at the same time, top line results outshined analysts by $ 0.93 million or 150.00 percent.
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of Co-Diagnostics, Inc.
Stock Performance
According to the previous trading day, closing price of CODX was $ 19.57, representing a 2,202.35 % increase from the 52 week low of $ 0.85 and a 36.85 % decrease over the 52 week high of $ 30.99.
The company has a market capital of $ 537.34 million and is part of the Healthcare sector and Diagnostics & Research industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”CODX” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Co-Diagnostics, Inc., a molecular diagnostics company, intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules. It also intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was founded in 2013 and is headquartered in Salt Lake City, Utah.
